HLS Therapeutics Inc (DE:74D)
FRANKFURT:74D

HLS Therapeutics Inc Stock Price & Analysis

0 Followers

74D Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€5.90 - €11.09
Previous Close€6.65
Volume0.00
Average Volume (3M)N/A
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$21.16M
Total Debt (Recent Filing)$91.63M
Price to Earnings (P/E)N/A
Beta1.13
Next EarningsMar 23, 2023
EPS Estimate-€0.08
Dividend Yield0.15 (2.13%)
EPS (TTM)N/A
Shares Outstanding32,407,318
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Price to Book (P/B)1.67
Price to Sales (P/S)2.71
Price to Cash Flow (P/CF)13.10
P/FCF Ratio215.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside167.12% Upside
Rating ConsensusModerate Buy
AlphaN/A
Number of Analyst Covering2


Financials


74D FAQ

What was HLS Therapeutics Inc’s price range in the past 12 months?
HLS Therapeutics Inc lowest stock price was €5.90 and its highest was €11.09 in the past 12 months.
    What is HLS Therapeutics Inc’s market cap?
    Currently, no data Available
    When is HLS Therapeutics Inc’s upcoming earnings report date?
    HLS Therapeutics Inc’s upcoming earnings report date is Mar 23, 2023 which is in 114 days.
      How were HLS Therapeutics Inc’s earnings last quarter?
      HLS Therapeutics Inc released its earnings results on Nov 10, 2022. The company reported -€0.135 earnings per share for the quarter, missing the consensus estimate of -€0.118 by -€0.017.
        Is HLS Therapeutics Inc overvalued?
        According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does HLS Therapeutics Inc pay dividends?
          HLS Therapeutics Inc pays a Quarterly dividend of €0.04 which represents an annual dividend yield of 2.13%. HLS Therapeutics Inc’s last Quarterly dividend payment was on Mar 15, 2023. HLS Therapeutics Inc’s upcoming ex-dividend date is Jan 30, 2023
            What is HLS Therapeutics Inc’s EPS estimate?
            HLS Therapeutics Inc’s EPS estimate is -€0.08.
              How many shares outstanding does HLS Therapeutics Inc have?
              Currently, no data Available
              What happened to HLS Therapeutics Inc’s price movement after its last earnings report?
              HLS Therapeutics Inc reported an EPS of -€0.135 in its last earnings report, missing expectations of -€0.118. Following the earnings report the stock price went down -4.861%.
                Which hedge fund is a major shareholder of HLS Therapeutics Inc?
                Currently, no hedge funds are holding shares in DE:74D

                ---

                HLS Therapeutics Inc Stock Smart Score

                3
                Underperform
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -43.97%
                12-Months-Change

                Fundamentals

                Return on Equity
                -14.02%
                Trailing 12-Months
                Asset Growth
                -4.37%
                Trailing 12-Months
                The HLS Therapeutics Inc Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                HLS Therapeutics Inc

                HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada and the United States.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Profound Medical
                BELLUS Health
                Aurinia Pharmaceuticals
                Medicenna Therapeutics Corp

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis